 WATERTOWN, Mass., June 14, 2021 GLOBE NEWSWIRE -- C4 Therapeutics, Inc. C4T Nasdaq: CCC, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock. 